**Impact of intensified antiretroviral therapy during early HIV infection on gut immunology and inflammatory blood biomarkers: a randomized controlled trial**

Connie J Kim1,2, Rodney Rousseau2, Sanja Huibner2, Colin Kovacs3, Erika Benko3, Kamnoosh Shahabi2, Gabor Kandel4, Mario Ostrowski1,4, Rupert Kaul1,2

1University Health Network, Toronto, Ontario, Canada (CJK, RK)

2Departments of Medicine and Immunology, University of Toronto, Toronto, Ontario, Canada (CJK, RR, KS, RK)

3Maple Leaf Medical Clinic, Toronto, Ontario, Canada (CK, EB)

4St. Michael’s Hospital, Toronto, Ontario, Canada (GK, MO)

**Correspondence**

Connie J Kim / Rupert Kaul, Department of Medicine, University of Toronto

Medical Sciences Building, Rm 6356, Toronto, Ontario, Canada, M5S 1A8

Tel: 1-416-946-7054, Fax: 1-416-978-8765

**Short title:** Intensified ART during early HIV infection

****

**Supplemental Figure 1.** Blood levels of (a) CD8 T cell activation, (b) IL-6, (c) D-dimer, (d) IL-17, (e) MIP1b, (f) IL-10, (g) sCD14, and (h) TNF at baseline and after 48 weeks of ART (pooled across sART and iART) vs. HIV-uninfected controls. Mann-Whitney U test was used to compare independent groups and Wilcoxon test was applied for paired analysis between baseline and week 48.